Moderna, Inc. (NASDAQ:MRNA) Given Consensus Recommendation of “Hold” by Analysts

Shares of Moderna, Inc. (NASDAQ:MRNA) have earned a consensus recommendation of “Hold” from the twenty brokerages that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $97.18.

A number of equities research analysts have weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Friday, September 13th. Leerink Partners cut their target price on Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a research report on Tuesday, September 17th. Royal Bank of Canada restated a “sector perform” rating and issued a $75.00 target price on shares of Moderna in a research report on Thursday, September 19th. The Goldman Sachs Group cut their target price on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research report on Monday, September 16th. Finally, Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and cut their target price for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th.

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $119.96, for a total value of $1,799,400.00. Following the transaction, the director now directly owns 2,224,015 shares of the company’s stock, valued at approximately $266,792,839.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $119.96, for a total value of $1,799,400.00. Following the transaction, the director now directly owns 2,224,015 shares of the company’s stock, valued at approximately $266,792,839.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 18,184 shares of company stock valued at $2,037,931 in the last three months. 15.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Moderna

Several hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Moderna by 15.1% during the first quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock worth $4,159,769,000 after buying an additional 5,129,800 shares during the last quarter. Capital World Investors boosted its holdings in Moderna by 0.5% during the first quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock valued at $388,743,000 after acquiring an additional 18,728 shares during the period. Mawer Investment Management Ltd. boosted its holdings in Moderna by 6.7% during the first quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock valued at $204,230,000 after acquiring an additional 120,621 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Moderna by 42.9% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock valued at $164,724,000 after acquiring an additional 463,960 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Moderna by 2.1% during the second quarter. Dimensional Fund Advisors LP now owns 1,427,300 shares of the company’s stock valued at $169,542,000 after acquiring an additional 29,566 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $53.39 on Thursday. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The stock has a 50 day simple moving average of $69.03 and a 200-day simple moving average of $103.55. The company has a market cap of $20.46 billion, a PE ratio of -3.41 and a beta of 1.66. Moderna has a 12-month low of $52.77 and a 12-month high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.47) by $0.14. The business had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business’s revenue was down 29.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($3.62) earnings per share. On average, equities research analysts forecast that Moderna will post -9.85 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.